Spots Global Cancer Trial Database for unresectable malignant solid neoplasm

Every month we try and update this database with for unresectable malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	NCT02898207	Metastatic High... Metastatic Mali... Metastatic Prim... Metastatic Trip... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Breas... Recurrent High ... Recurrent High ... Recurrent Prima... Recurrent Tripl... Refractory Fall... Refractory Ovar... Refractory Prim... Refractory Trip... Unresectable Hi... Unresectable Ma... Unresectable Pr...	Olaparib Onalespib	18 Years -	National Cancer Institute (NCI)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	NCT05687110	Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Diagnostic Imag... Novobiocin Sodi...	18 Years -	National Cancer Institute (NCI)
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	NCT05554380	Locally Advance... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor	NCT04800627	Locally Advance... Metastatic Mali... Unresectable Ma...	Pembrolizumab Pevonedistat	18 Years -	M.D. Anderson Cancer Center
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	NCT03872427	Advanced Malign... Metastatic Mali... NF1 Mutation Po... Unresectable Ma...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Pharmacodynamic... Positron Emissi... Telaglenastat H...	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	NCT04673448	Anatomic Stage ... Anatomic Stage ... BRCA-Associated... BRCA-Associated... Metastatic BRCA... Metastatic Brea... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Prim... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Br... Unresectable Fa... Unresectable Ma... Unresectable Ov... Unresectable Pa... Unresectable Pr...	Dostarlimab Niraparib	18 Years -	University of Washington
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer	NCT02862275	Hematopoietic a... Metastatic Mali... Unresectable Ma...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment	NCT04168320	Bystander Effec... Abscopal Effect Unresectable Ma... Bulky Tumors	SBRT-PATHY (SBR...	18 Years - 100 Years	Klinikum Klagenfurt am Wörthersee
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors	NCT03030378	Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Edodekin alfa Magnetic Resona... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	NCT05111561	Advanced Malign... Metastatic Mali... Refractory Mali... Triple-Negative... Unresectable Ma...	BET Bromodomain... Binimetinib Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	NCT04294628	Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers	NCT05803382	Metastatic Colo... Metastatic Mali... Stage IV Colore... Unresectable Co... Unresectable Ma...	BET Bromodomain... Biopsy Biospecimen Col... Capecitabine Computed Tomogr... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer	NCT04585958	Endometrial Ser... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Olaparib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	NCT04387071	Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma...	Agonistic Anti-... VLP-encapsulate...	18 Years -	University of Southern California
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial	NCT05327010	Advanced Malign... Metastatic Mali... Unresectable Ma...	BET Bromodomain... Biopsy Biospecimen Col... Diagnostic Imag... Talazoparib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer	NCT04585958	Endometrial Ser... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Olaparib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment	NCT04168320	Bystander Effec... Abscopal Effect Unresectable Ma... Bulky Tumors	SBRT-PATHY (SBR...	18 Years - 100 Years	Klinikum Klagenfurt am Wörthersee
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	NCT04387071	Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma...	Agonistic Anti-... VLP-encapsulate...	18 Years -	University of Southern California
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	NCT04294628	Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study	NCT04197713	Advanced Malign... Metastatic Mali... Refractory Mali... Unresectable Ma...	Adavosertib Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	NCT03842228	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Copanlisib Hydr... Durvalumab Echocardiograph... Magnetic Resona... Olaparib X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	NCT05111561	Advanced Malign... Metastatic Mali... Refractory Mali... Triple-Negative... Unresectable Ma...	BET Bromodomain... Binimetinib Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	NCT04266912	Metastatic Mali... Refractory Mali... Unresectable Ma...	Avelumab Berzosertib	18 Years -	M.D. Anderson Cancer Center
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02595931	Metastatic Colo... Metastatic Lung... Metastatic Mali... Metastatic Panc... Refractory Colo... Refractory Lung... Refractory Mali... Refractory Panc... Stage III Color... Stage III Lung ... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... Unresectable Co... Unresectable Lu... Unresectable Ma... Unresectable Pa...	Berzosertib Biopsy Specimen Biospecimen Col... Computed Tomogr... Irinotecan Hydr...	18 Years -	National Cancer Institute (NCI)
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer	NCT02862275	Hematopoietic a... Metastatic Mali... Unresectable Ma...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	NCT03842228	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Copanlisib Hydr... Durvalumab Echocardiograph... Magnetic Resona... Olaparib X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	NCT04514497	Metastatic Lung... Metastatic Mali... Metastatic Neur... Metastatic Panc... Stage III Lung ... Stage III Pancr... Stage IV Lung C... Stage IV Pancre... Unresectable Lu... Unresectable Ma... Unresectable Ne... Unresectable Pa...	Biopsy Biospecimen Col... Computed Tomogr... Elimusertib Irinotecan Hydr... Magnetic Resona... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN	NCT04317105	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Copanlisib Hydr... Echocardiograph... Ipilimumab Nivolumab X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	NCT01364051	Metastatic Mela... Refractory Mali... Stage IV Cutane... Unresectable Ma...	Cediranib Cediranib Malea... Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: